Mustang Bio (MBIO) Competitors $0.27 -0.01 (-3.61%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MBIO vs. RLYB, ATRA, ORGS, CARM, ACHL, EQ, NXTC, VYNE, ELEV, and MRKRShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Rallybio (RLYB), Atara Biotherapeutics (ATRA), Orgenesis (ORGS), Carisma Therapeutics (CARM), Achilles Therapeutics (ACHL), Equillium (EQ), NextCure (NXTC), VYNE Therapeutics (VYNE), Elevation Oncology (ELEV), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. Rallybio Atara Biotherapeutics Orgenesis Carisma Therapeutics Achilles Therapeutics Equillium NextCure VYNE Therapeutics Elevation Oncology Marker Therapeutics Mustang Bio (NASDAQ:MBIO) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk. Do analysts prefer MBIO or RLYB? Mustang Bio presently has a consensus price target of $2.00, indicating a potential upside of 648.78%. Rallybio has a consensus price target of $10.00, indicating a potential upside of 890.10%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than Mustang Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is MBIO or RLYB more profitable? Rallybio's return on equity of -74.08% beat Mustang Bio's return on equity.Company Net Margins Return on Equity Return on Assets Mustang BioN/A -1,243.22% -191.57% Rallybio N/A -74.08%-67.07% Which has more risk & volatility, MBIO or RLYB? Mustang Bio has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.67, meaning that its stock price is 267% less volatile than the S&P 500. Does the media prefer MBIO or RLYB? In the previous week, Rallybio had 1 more articles in the media than Mustang Bio. MarketBeat recorded 2 mentions for Rallybio and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.05 beat Rallybio's score of 0.17 indicating that Mustang Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mustang Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in MBIO or RLYB? Mustang Bio received 131 more outperform votes than Rallybio when rated by MarketBeat users. However, 76.00% of users gave Rallybio an outperform vote while only 64.26% of users gave Mustang Bio an outperform vote. CompanyUnderperformOutperformMustang BioOutperform Votes16964.26% Underperform Votes9435.74% RallybioOutperform Votes3876.00% Underperform Votes1224.00% Do institutionals & insiders believe in MBIO or RLYB? 9.9% of Mustang Bio shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 0.8% of Mustang Bio shares are owned by insiders. Comparatively, 7.4% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings & valuation, MBIO or RLYB? Rallybio is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMustang BioN/AN/A-$51.60M-$2.75-0.10RallybioN/AN/A-$74.56M-$1.79-0.56 SummaryRallybio beats Mustang Bio on 9 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.95M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.109.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book26.715.324.665.02Net Income-$51.60M$153.56M$119.06M$225.46M7 Day Performance-7.86%0.11%0.80%0.37%1 Month Performance21.24%15.22%5.65%3.57%1 Year Performance-83.31%41.14%36.76%29.44% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio2.5937 of 5 stars$0.27-3.6%$2.00+648.8%-83.0%$9.95MN/A-0.10100Gap DownRLYBRallybio3.1463 of 5 stars$1.03+4.0%$10.00+870.9%-76.1%$42.69M$299,000.00-0.5840Analyst ForecastPositive NewsATRAAtara Biotherapeutics3.5786 of 5 stars$8.60+1.7%$14.00+62.8%-69.2%$41.43M$62.39M-0.22165Upcoming EarningsGap UpORGSOrgenesis1.8579 of 5 stars$1.20+0.8%N/AN/A$41.34M$662,000.000.00150Positive NewsGap DownCARMCarisma Therapeutics2.6058 of 5 stars$1.00flat$7.00+600.0%-65.6%$40.71M$14.92M-0.5620Analyst UpgradeNews CoverageGap UpACHLAchilles Therapeutics2.8564 of 5 stars$0.98flat$4.00+308.2%+21.4%$40.27MN/A-0.62250Positive NewsEQEquillium2.4197 of 5 stars$1.18-3.3%$5.00+323.7%+67.6%$38.97M$36.08M-4.7240Short Interest ↑News CoverageNXTCNextCure3.888 of 5 stars$1.39+3.0%$6.00+331.7%+24.3%$38.88MN/A-0.6390Upcoming EarningsPositive NewsGap UpVYNEVYNE Therapeutics2.8869 of 5 stars$2.67-0.7%$5.75+115.4%-11.4%$38.79M$486,000.00-1.0330Gap UpELEVElevation Oncology1.956 of 5 stars$0.58-6.4%$7.80+1,240.2%+23.2%$38.64MN/A-0.6840Upcoming EarningsMRKRMarker Therapeutics3.5555 of 5 stars$4.33+8.0%$19.00+339.3%+28.9%$38.58M$3.31M0.0060Gap Up Related Companies and Tools Related Companies RLYB Alternatives ATRA Alternatives ORGS Alternatives CARM Alternatives ACHL Alternatives EQ Alternatives NXTC Alternatives VYNE Alternatives ELEV Alternatives MRKR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MBIO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
